Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

Also called NCT00117936

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Venturis Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT00117936
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT00117936. Randomized; double masking; primary purpose treatment. Start 2027-09-01 (anticipated); primary completion 2029-11-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
Condition
Coronary Disease
Condition
Coronary Heart Disease
Condition
Myocardial Ischemia
Condition
Coronary Arteriosclerosis
Intervention (Combination product)
Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose
Intervention (Combination product)
Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
Intervention (Combination product)
Placebo
Lead sponsor
Venturis Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct00117936
Content hash
452d602749a2a86760126516f579d1259db8774d17688d355d47d5809a52f51d